Min Hee Hong
Yonsei University · 医学
研究室紹介
Professor Min Hee Hong's research lab focuses on advanced materials synthesis and their applications in energy and biomedical technologies. The lab specializes in the development of doped mesoporous metal oxide thin films, particularly Al-doped ZnO, for enhanced electrical and structural properties suitable for optoelectronic devices. In parallel, the lab conducts clinical oncology research, particularly in targeted and chemotherapy regimens for advanced or metastatic cancers such as renal cell carcinoma, esophageal squamous cell carcinoma, and salivary gland cancer, with an emphasis on treatment efficacy, safety, and biomarker-driven therapy. The integration of materials science and translational oncology defines the lab’s interdisciplinary approach.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Al‐doped mesoporous ZnO thin films were synthesized by a sol‐gel process and an evaporation‐induced self‐assembly process. In this work, the effects of Al doping concentration on the electrical conductivity and characterization of mesoporous ZnO thin films were investigated. By changing the Al doping concentration, ZnO grain growth is inhibited, and the mesoporous structure of ZnO is maintained during a relatively high temperature annealing process. The porosity of Al‐doped mesoporous ZnO thin f
Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
4027 Background: Even though preoperative chemoradiotherapy (CRT) showed survival improvement in patients with resectable ESCC in a randomized trial over upfront surgery, ESCC still has a dismal prognosis. With the potential benefit of combining PD-1 blockade to CRT, we conducted a phase II trial which assessed the efficacy, feasibility, and safety of the combination of preoperative CRT and pembrolizumab (PEM) in ESCC. Methods: Patients (pts) with histologically confirmed ESCC (clinical stage Ib
Abstract Background The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods In this single‐arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective
It is well known that the adrenal medulla contains high concentrations of neuropeptide Y (NPY) where it coexists with epinephrine and norepinephrine. In order to evaluate the possible involvement of NPY in the regulation of the chromafin cells of the rat adrenal medulla, we have studied the effects of NPY and some NPY analogs on the concentrations of tyrosine hydroxylase (TH) mRNA. The following peptides, NPY, PYY, [Leu31, Pro34]-NPY (a Y1 receptor agonist) and NPY13-36 (a Y2 receptor agonist) w
Approximately 60% of patients in the analyzed real-world cohort were eligible for tissue rebiopsy upon NSCLC progression. Osimertinib activity was higher in patients in whom T790M mutations were detected in tissues rather than in plasma samples.
Abstract With the increasing oncological potential of immunotherapy, several immune checkpoint modulators are being investigated. The value of immune markers, including programmed cell death ligand-1, programmed cell death-1 (PD-1), inducible co-stimulator (ICOS), lymphocyte activation gene-3, T-cell immunoglobulin, and mucin-dominant containing-3 (TIM-3), is not well known. Using tissue microarrays of 396 patients who underwent surgery for oesophageal squamous cell carcinoma (ESCC), infiltrated